Amplification of the EGFR gene and mutations of the EGFR tyrosine kinase domain, which leads to EGFR hyperactivity, have been demonstrated to occur in various solid tumors.33 It is of interest that REP1 knockdown downregulates, and thus inactivates EGFR because EGFR inactivation is a critical strategy to control cancer. Here, CHM is linked to cancer.